{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ranzani OT"],"funding":["Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)"],"pagination":["5536"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9537178"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6-11.5) and 56.8% (95% CI, 56.3-57.3) in the period 8-59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9-80.7) and 86.0% (95% CI, 84.5-87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine."],"journal":["Nature communications"],"pubmed_title":["Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil."],"pmcid":["PMC9537178"],"funding_grant_id":["Sara Borrell fellowship (CD19/00110)"],"pubmed_authors":["Said RFC","Dean NE","Cummings DAT","Andrews JR","Tsuha DH","David LCS","Lind ML","Croda J","de Melo RL","Fernandes CFR","Ranzani OT","de Franca GVA","Ko AI","Torres MSS","Almiron M","Hitchings MDT","de Oliveira RD"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil.","description":"The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6-11.5) and 56.8% (95% CI, 56.3-57.3) in the period 8-59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9-80.7) and 86.0% (95% CI, 84.5-87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-18T21:00:10.313Z","creation":"2025-04-07T08:59:19.376Z"},"accession":"S-EPMC9537178","cross_references":{"pubmed":["36202800"],"doi":["10.1038/s41467-022-33169-0"]}}